The Global Health Technologies Coalition 2020 Innovating for Impact Partnership award recognizes CARB-X for its work to transform breakthrough scientific research into lifesaving drugs, diagnostics, vaccines, and other products to combat antibiotic-resistant bacteria.
Antibiotic resistance is one of the greatest global health threats of our time. Antibiotics are vital tools for addressing bacterial infections and save untold millions of lives each year. However, the increasing prevalence of resistant strains of bacteria threatens the usefulness of antibiotics and can cause untreatable infections. CDC’s 2019 Report on Antibiotic Resistance Threats estimates that each year, more than 2.8 million Americans develop a drug-resistant infection, and more than 35,000 die from them.
Globally, drug-resistant infections kill over 700,000 people every year, and in the United Nations’ report No Time to Wait, warns that without a sustained effort to contain antimicrobial resistance (AMR), this figure could increase to 10 million lives lost per year by 2050, with 2.4 million deaths occurring in high-income countries between 2015 and 2050.
The U.S. government is committed to fostering partnerships that work to increase the pipeline of urgently needed new antimicrobial products. In 2016, BARDA co-founded the biopharmaceutical accelerator CARB-X, to deliver high-impact technologies to combat the AMR threat. The CARB-X program was conceptualized, developed, and launched with support from the National Institute of Allergy and Infectious Diseases (NIAID) and the Wellcome Trust, and is managed by Boston University. Today, with additional support from the UK’s Global AMR Innovation Fund, the German Federal Ministry of Education and Research, and the Bill & Melinda Gates Foundation, CARB-X has become one of the world’s largest public-private partnerships focused on preclinical development of new antibacterial products.
Since its inception, CARB-X has provided funding, technical guidance, and business support to 75 diverse and innovative projects in 10 countries to develop innovative antibacterial therapeutics, vaccines, rapid diagnostics, and other life-saving products. Several projects have successfully met early milestones to date and are poised to increase the pipeline of antibacterial products and respond to the AMR global threat. BARDA remains dedicated to promoting innovation to save lives and combat antibiotic-resistant bacteria.